 |
|
|
| |
Efficacy and Safety of Elbasvir/Grazoprevir for
8 or 12 Weeks
in Participants With Hepatitis C Virus
Genotype 4 Infection
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-12 Boston
Tarik Asselah1; Stanislas Pol2; Christophe Hezode3; Veronique Loustaud-Ratti4; Vincent Leroy5; Si Nafa Si Ahmed6;
Violaine Ozenne7; Jean-Pierre Bronowicki8; Dominique Larrey9; Albert Tran10; Laurent Alric11; Eric Nguyen-Khac12;
Michael N. Robertson13; George J. Hanna13; Deborah Brown13; Ernest Asante-Appiah13; Steve Ludmerer13; Feng-Hsiu Su13;
Peggy Hwang13; Stephanie Klopfer13; Jessie Durrand Hall13; Amir Guidoum13; Karin Hagen13; Barbara A. Haber13;
Rohit Talwani13; Lawrence Serfaty14
1Hopital Beaujon, Clichy, France; 2APHP/Universite Paris Descartes, Paris, France; 3Henri Mondor Hospital, Creteil, France; 4CHU Limoges,
Limoges, France; 5CHU Grenoble Alpes, Grenoble, France; 6Pole de Recherche Clinique, Hepato Gastroenterologie, Hopital Saint Joseph,
Marseille, France; 7Hopital Saint Antoine, Paris, France; 8CHU Nancy, Nancy, France; 9Hopital Saint Eloi, Montpellier School of Medicine, Montpellier,
France; 10Hopital l'Archet 2, Nice, France; 11CHU de Toulouse, Toulouse, France; 12CHU Amiens, Amiens, France; 13Merck & Co., Inc.,
Kenilworth, NJ, USA; 14Hopital de Hautepierre, Universitaires de Strasbourg, Strasbourg, France
|
| |
|
|
|
|
|
